Skip to main content
. 2020 Nov 22;97(Suppl 1):S49–S58. doi: 10.1016/j.jped.2020.10.009

Table 8.

Immunobiological agents and risk of infection.

Class/mechanism of action Medications Higher risk of infection
Tumor necrosis factor (anti-TNF) antagonists Etanercept
Adalimumab
Infliximab
Tuberculosis
Fungal, bacterial and viral infections
T lymphocyte co-stimulation blocker (CTLA4-Ig) Abatacept Worsening of active infections by any pathogen
B lymphocyte depletion (anti-CD20) Rituximab Reactivation of the Hepatitis B virus
Interleukin 6 (IL-6) receptor blocker Tocilizumab Worsening of active infections by any pathogen

Adapted from da Mota et al.17